LifeForce Capital

LifeForce runs a concentrated, long-biased public-equity strategy focused exclusively on healthcare — spanning biotechnology, life sciences tools, diagnostics, and healthcare technology. The firm targets small- to mid-cap companies where it can take meaningful ownership stakes and engage constructively with management teams around capital allocation, pipeline strategy, and operational execution.

LifeForce stays entirely within healthcare, avoiding sectors outside its circle of competence — including energy, financials, consumer goods, and general technology. Within healthcare, the firm historically avoids large-cap pharmaceuticals with entrenched pipelines and payer-facing service companies where pricing power is constrained by government reimbursement.

Galbo pursues constructive engagement rather than hostile activism. The firm takes concentrated positions and uses its stake to discuss capital allocation, pipeline prioritization, and operational milestones with management and boards. It has not waged proxy fights or publicly agitated for C-suite turnover in any disclosed campaign.